[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587268":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":78,"collaborators":7,"id":81,"slug":7,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":7,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":7,"enrollmentInfo":89,"targetDuration":7,"studyType":92,"phases":7,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","neoadjuvant immunotherapy","Patients in the cohort received neoadjuvant immune checkpoint inhibitors (ICIs), including PD-1\u002FPD-L1 inhibitors, as part of routine clinical care. The specific regimens included monotherapy or combination with chemotherapy. The agents used may include nivolumab, camrelizumab, sintilimab, atezolizumab, or others.\n\nThis is a retrospective observational study. All interventions (neoadjuvant immunotherapy ± chemotherapy, surgery, or other treatments) were determined by treating physicians as part of standard care. The study aims to evaluate perioperative and survival outcomes across different treatment paths in real-world clinical settings.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Nan Wu, MD","CONTACT","0086-10-88196569","nanwu@bjmu.edu.cn",[20,36,48,63],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Beijing","Beijing Municipality","100142","China",{"type":27,"coordinates":28},"Point",[29,30],116.39723,39.9075,{"lat":30,"lon":29},[33,34],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"name":15,"role":35,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"facility":37,"status":21,"city":22,"state":23,"zip":7,"country":25,"cosmosGeoPoint":38,"geoPoint":40,"contacts":41},"Peking University Third Hospital",{"type":27,"coordinates":39},[29,30],{"lat":30,"lon":29},[42,46],{"name":43,"role":16,"phone":44,"phoneExt":7,"email":45},"Guangliang Qiang, MD","86-010-82267600","pkudd@bjmu.edu.cn",{"name":43,"role":47,"phone":7,"phoneExt":7,"email":7},"SUB_INVESTIGATOR",{"facility":49,"status":21,"city":50,"state":51,"zip":7,"country":25,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Inner Mongolia Hospital of Peking University Cancer Hospital","Hohhot","Inner Mongolia",{"type":27,"coordinates":53},[54,55],111.65222,40.81056,{"lat":55,"lon":54},[58,62],{"name":59,"role":16,"phone":60,"phoneExt":7,"email":61},"Bateer Han, MD","86-13948120033","hanbateer_2004@163.com",{"name":59,"role":47,"phone":7,"phoneExt":7,"email":7},{"facility":64,"status":21,"city":65,"state":66,"zip":7,"country":25,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"The Third Affliated Hospital of Kunming Medical University","Kunming","Yunnan",{"type":27,"coordinates":68},[69,70],102.71833,25.03889,{"lat":70,"lon":69},[73,77],{"name":74,"role":16,"phone":75,"phoneExt":7,"email":76},"Yujie Lei, MD","86-0871-68173760","583271025@qq.com",{"name":74,"role":47,"phone":7,"phoneExt":7,"email":7},{"type":35,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Wu Nan","Professor","100587268",false,"NCT06926179","Safety, Efficacy, and Survival Outcomes of Neoadjuvant\u002FInduction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer","Safety, Efficacy, and Survival Outcomes of Neoadjuvant\u002FInduction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer: A Multicenter Real-World Study","Inclusion Criteria:\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC), regardless of the presence of EGFR or ALK sensitive driver gene mutations;\n2. Clinical staging of IA-IIIC according to the AJCC 8th Edition before neoadjuvant treatment;\n3. Received at least one cycle of neoadjuvant immunotherapy (with or without chemotherapy);\n4. Assessed as resectable or potentially resectable by surgical experts prior to treatment.\n\nExclusion Criteria:\n\n1. Confirmed M1 disease;\n2. History of previous lung malignancy or other metastatic malignant tumors;\n3. Participation in other randomized controlled trials involving neoadjuvant treatment;\n4. Significant missing clinical data.","ALL","18 Years",{"count":90,"type":91},500,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant\u002Finduction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant\u002Finduction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.",[95,96,97,98],"Lung Cancer (NSCLC)","Neoadjuvant Immunotherapy","Radiotherapy","Lung Surgery",[100,11,101,102,103],"lung cancer","real-world study","radiotherapy","thoracic surgery","2025-04-11",{"date":106,"type":107},"2025-04-16","ACTUAL",{"date":109,"type":107},"2024-12-01",{"date":111,"type":91},"2028-03-31",{"name":5,"class":6},4]